References
- Keating M J, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079–4088
- Kay N E, Geyer S M, Call T G, Shanafelt T D, Zent C S, Jelinek D F, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated b chronic lymphocytic leukemia. Blood 2007; 109: 405–411
- Michallet M, Archimbaud W, Bandini G, Rowlings P A, Deeg H J, Gahrton G, et al. HLA-indentical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group For Blood And Marrow Transplantation And The International Bone Marrow Transplant Registry. Ann Intern Med 1996; 124: 311–315
- Pavletic Z S, Arrowsmith E R, Bierman P J, Goodman S A, Vose J M, Tarantolo S R, et al. Outcome of allogeneic stem cell transplantation for b cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717–722
- Pavletic S Z, Khouri I F, Haagenson M, King R J, Bierman P J, Bishop M R, et al. Unrelated donor bone marrow transplantation for b-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center For International Blood And Marrow Transplant Research. J Clin Oncol 2005; 23: 5788–5794
- Moreno C, Villamor N, Colomer D, Esteve J, Matino R, Nomdedeu J, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated vh gene is patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3433–3438
- Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G, et al. Reduced-intensity conditioning lowers treatment-realted mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005; 19: 1029–1033
- Caballero D, Garcia-Marco J A, Martino R, Mateos V, Ribera J M, Sarra J, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of b-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005; 11: 7757–7763
- Sorror M L, Maris M B, Sandmaier B M, Storer B E, Stuart M J, Hegenbart U, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819–3829
- Schetelig J, Thiede C, Bornhauser M, Scwerdtfeger R, Kiehl M, Beyer J, et al. evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753
- Ritgen M, Stilgenbauer S, Von Neuhoff N, Humpe A, Bruggemann M, Pott C, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600–2602
- Khouri I F, Saliba R M, Admirand J, O'Brien S, Lee M S, Korbling M, et al. Graft-versus-leukemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haem 2007; 137: 355–363
- Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT Transplant Consensus. Leukemia 2007; 21: 12–17
- Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How i treat refractory CLL. Blood 2006; 107: 1276–1283
- Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841–848
- Doney K C, Chauncey T, Appelbaum F R. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 2002; 29: 817–823
- Michallet M M, Michallet A S, Le Q H, Bandini G, Rowlings P A, Deeg H J, et al. Conventional HLA-identical sibling bone marrow transplantation is able to cure chronic lymphocytic leukemia. A Study From The EBMT And IBMT Registries. Blood 2003; 1729a
- Hertzberg M, Grigg A, Gottlieb D, Szer J, Roberts A, Hoyt R, et al. Reduced-intensity allogeneic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone Marrow Transplant 2006; 37: 923–928
- Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
- Przepiorka D, Weisdorf D, Martin P, Klingemann H G, Beatty P, Hows J, Thomas E D. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828
- Cordone I, Masi S, Mauro F R, Soddu S, Morsilli O, Valentini T, et al. P53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998; 91: 4342–4349
- Esteve J, Montserrat E, Dreger P, Meloni G, Pavletic S, Catovsky D, et al. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): outcome and prognostic factors after autologous and allogeneic transplants. Blood 2001; 2013a
- Bevans M F, Marden S, Leidy N K, Soeken K, Cusack G, Rivera P, et al. Health-related quality of life inpatients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 101–109